Setazindol

Setazindol

Setazindol is a drug that was developed in the 1970s by the pharmaceutical industry. It is classified as an anorectic, which means it is used to suppress or reduce appetite. Setazindol is part of a larger class of drugs known as stimulants, which are substances that increase activity in the central nervous system and the body.

History

Setazindol was first synthesized in the 1970s by the pharmaceutical company Hoffmann-La Roche. It was developed as part of a wave of new anorectic drugs that were being produced and marketed at the time. However, unlike many of its contemporaries, Setazindol was never widely used or commercially successful.

Pharmacology

As an anorectic, Setazindol works by suppressing the appetite. This is achieved by stimulating the release of certain chemicals in the brain that control feelings of hunger and fullness. Setazindol is also a stimulant, which means it increases activity in the central nervous system and the body. This can lead to increased heart rate, blood pressure, and metabolism, among other effects.

Side Effects

Like all drugs, Setazindol can have side effects. These can include insomnia, nervousness, irritability, and dry mouth. In rare cases, it can also cause more serious side effects such as heart palpitations, high blood pressure, and psychosis. Due to these potential side effects, Setazindol is typically only prescribed for short-term use.

Legal Status

Setazindol is a controlled substance in many countries, including the United States, where it is classified as a Schedule IV controlled substance. This means it has a low potential for abuse and is available only by prescription.

See Also

• Anorectic
• Stimulant
• Hoffmann-La Roche

This article is a stub related to pharmacology. You can help WikiMD by expanding it!